Purdue Pharma L.P. (Purdue) announced that the company has partnered with MMCAP Infuse to provide buprenorphine and naloxone tablets CIII (generic Suboxone), a medication for opioid use disorder (MOUD), at low cost to correctional facilities for incarcerated individuals with opioid use disorder. MMCAP Infuse is a national cooperative group purchasing organization operated by the State of Minnesota, Office of State Procurement, for government facilities that provide healthcare services. Under the agreement, to increase access to treatment for incarcerated individuals, Purdue will provide for distribution approximately 1.25 million tablets at the cost of one penny ($0.01) per tablet.
Enforcement Report - Week of November 15, 2023
Sun Pharma's Generic Buprenorphine & Naloxone Hydrochloride Receives Approval in the U.S.
Enforcement Report - Week of February 1, 2023
Suboxone settlement boosts Dr. Reddy’s Q1 net
Today, Wednesday, July 22, at the national conference of the Social Security Investment Company (Shasta), which will be held at the place of radio and television conferences with the aim of introducing the position of Shasta in the national economy, the pharmaceutical raw materials production company (Temad) is one of the group companies. Tamin Medicine (Tpico) will unveil three new and innovative products, two of which are produced for the first time in the country.
Aveva`s Generic Buprenorphine HCL Naloxone HCL Receives Approval in the U.S.
Alvogen`s Generic Buprenorphine HCl Receives Approval In US
Alkem`s Generic Buprenorphine HCl; Naloxone HCl Receives Approval In US